Please wait while the formulary information is being retrieved.
DRUG IMAGES
BETAMETHASONE VA 0.1% CREAM
BETAMETHASONE VALER 0.12% FOAM
The following indications for BETAMETHASONE VALERATE (betamethasone valerate) have been approved by the FDA:
Indications:
Allergic dermatitis
Atopic dermatitis
Contact dermatitis
Cutaneous T-cell lymphoma
Dermatosis of the scalp
Discoid lupus erythematosus
Genital organ pruritus
Granuloma annulare
Lichen simplex chronicus
Plaque psoriasis
Pruritus ani
Pruritus of skin
Pyoderma gangrenosum
Scalp psoriasis
Seborrheic dermatitis
Skin inflammation
Professional Synonyms:
Atopic eczema
Circumscribed neurodermatitis
Dermatitis seborrheica
Dermatitis venenata
Dermatitis
Disseminated neurodermatitis
Dyssebacea
Dyssebacia
Genital pruritus
Itchy skin eruption
Lichen annularis
Primary cutaneous T-cell lymphoma
Pruritic dermatitis
Scalp dermatosis
Seborrhea corporis
Seborrheic eczema
Small cerebriform cell lymphoma
Unna's disease
Vidal's disease
Indications:
Allergic dermatitis
Atopic dermatitis
Contact dermatitis
Cutaneous T-cell lymphoma
Dermatosis of the scalp
Discoid lupus erythematosus
Genital organ pruritus
Granuloma annulare
Lichen simplex chronicus
Plaque psoriasis
Pruritus ani
Pruritus of skin
Pyoderma gangrenosum
Scalp psoriasis
Seborrheic dermatitis
Skin inflammation
Professional Synonyms:
Atopic eczema
Circumscribed neurodermatitis
Dermatitis seborrheica
Dermatitis venenata
Dermatitis
Disseminated neurodermatitis
Dyssebacea
Dyssebacia
Genital pruritus
Itchy skin eruption
Lichen annularis
Primary cutaneous T-cell lymphoma
Pruritic dermatitis
Scalp dermatosis
Seborrhea corporis
Seborrheic eczema
Small cerebriform cell lymphoma
Unna's disease
Vidal's disease
The following dosing information is available for BETAMETHASONE VALERATE (betamethasone valerate):
Betamethasone dipropionate and valerate are applied topically. Betamethasone dipropionate preparations and betamethasone valerate preparations should not be used with occlusive dressings and patients should be warned that treated areas of the skin should not be bandaged or otherwise covered or wrapped as to be occlusive, unless directed by a clinician.
Concentrations of the dipropionate and valerate preparations usually are expressed in terms of betamethasone. Concentration of betamethasone valerate foam is expressed in terms of betamethasone valerate.
Topical preparations of betamethasone dipropionate usually are applied sparingly in thin films and are rubbed gently into the affected area once or twice daily. Because betamethasone dipropionate preparations formulated in an optimized (augmented) vehicle are among the most potent topical corticosteroid preparations currently available, the manufacturers state that dosage of betamethasone dipropionate 0.05% ointments, creams, gels, or lotions in optimized (augmented) vehicles should not exceed 45 g, 45 g, 50 g, or 50 mL per week, respectively.
Some manufacturers also state that duration of therapy with these optimized preparations should not exceed 2 weeks.
Topical betamethasone 0.1% creams and ointments (as valerate) usually are applied sparingly in thin films and are rubbed gently into the affected area 1-3 times daily. However, once- or twice-daily administration of these preparations often is effective.
Topical betamethasone valerate 0.1% solutions are applied sparingly (e.g., a few drops) and are rubbed gently into the affected area twice daily, in the morning and evening. Dosage of the topical solution may be increased in patients with resistant dermatoses.
However, dosing frequency should be decreased to once daily following clinical improvement.
For relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp, betamethasone valerate 0.12% foam should be applied twice daily, in the morning and evening. For application to the scalp, the can containing betamethasone valerate foam should be inverted and small amounts of the preparation placed on a saucer or other cool surface.
The foam should not be dispensed directly to the hands since the foam will begin to melt immediately upon contact with warm skin. Small amounts of the preparation should be massaged gently into the scalp until the foam disappears and entire scalp area has been treated.
For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, or tinea corporis caused by Trichophyton mentagrophytes, T. rubrum, or Epidermophyton floccosum, the fixed-combination cream or lotion containing betamethasone 0.05% and clotrimazole 1% should be applied sparingly and rubbed gently into the affected area twice daily, in the morning and evening.
If clinical improvement does not occur after 1 week in the treatment of tinea cruris or tinea corporis or after 2 weeks in the treatment of tinea pedis, the diagnosis should be reevaluated. The manufacturer states that dosage of the combination cream or lotion should not exceed 45 g or 45 mL per week, respectively, and duration of therapy with these combination preparations should not exceed 2 weeks in the treatment of tinea cruris or tinea corporis or 4 weeks in the treatment of tinea pedis. Occlusive dressings should not be used with these combination preparations.
For the topical treatment of plaque psoriasis (psoriasis vulgaris) in adults 18 years of age or older, the fixed-combination ointment containing betamethasone 0.05% and calcipotriene 0.005% should be applied and rubbed gently into the affected area until absorbed once daily.
The combination ointment should not be applied to greater than 30% of body surface area. The manufacturer states that dosage of the combination ointment should not exceed 100 g per week, and duration of therapy should not exceed 4 consecutive weeks. Occlusive dressings should not be used with the combination preparation, unless directed by a clinician.
The fixed-combination ointment should not be applied to the face, axillae, or groin area. The fixed-combination ointment should not be used in patients with erythrodermic, exfoliative, or pustular psoriasis or in patients with preexisting atrophy at the treatment site. Contact with the eyes should be avoided.
If irritation occurs, therapy with the fixed-combination ointment should be discontinued and appropriate treatment instituted. Patients should wash their hands after applying the drug. The fixed-combination ointment is not for ophthalmic, oral, or intravaginal use.
For the topical treatment of moderate to severe plaque psoriasis (psoriasis vulgaris) of the scalp in adults 18 years of age or older, the fixed-combination suspension containing betamethasone 0.05% and calcipotriene 0.005% should be applied to the affected area(s) on the scalp once daily for 2 weeks or until cleared.
The manufacturer states that dosage of the combination suspension should not exceed 100 g per week, and duration of therapy should not exceed 8 weeks. Occlusive dressings should not be used with the combination preparation, unless directed by a clinician. The combination suspension should not be applied to the face, axillae, or groin area.
In addition, the suspension should not be used in patients with erythrodermic, exfoliative, or pustular psoriasis or in patients with preexisting atrophy at the treatment site. Contact with the eyes should be avoided; eye irritation may occur. The bottle containing the suspension should be shaken prior to each use; patients should wash their hands after applying the drug.
The fixed-combination suspension is not for ophthalmic, oral, or intravaginal use.
Because calcipotriene may increase the effect of ultraviolet radiation to induce skin tumors, patients who apply the fixed-combination ointment or suspension to exposed areas of the body should avoid exposure to natural or artificial (e.g., sunlamps, tanning booths) sunlight and limit or avoid phototherapy.
Concentrations of the dipropionate and valerate preparations usually are expressed in terms of betamethasone. Concentration of betamethasone valerate foam is expressed in terms of betamethasone valerate.
Topical preparations of betamethasone dipropionate usually are applied sparingly in thin films and are rubbed gently into the affected area once or twice daily. Because betamethasone dipropionate preparations formulated in an optimized (augmented) vehicle are among the most potent topical corticosteroid preparations currently available, the manufacturers state that dosage of betamethasone dipropionate 0.05% ointments, creams, gels, or lotions in optimized (augmented) vehicles should not exceed 45 g, 45 g, 50 g, or 50 mL per week, respectively.
Some manufacturers also state that duration of therapy with these optimized preparations should not exceed 2 weeks.
Topical betamethasone 0.1% creams and ointments (as valerate) usually are applied sparingly in thin films and are rubbed gently into the affected area 1-3 times daily. However, once- or twice-daily administration of these preparations often is effective.
Topical betamethasone valerate 0.1% solutions are applied sparingly (e.g., a few drops) and are rubbed gently into the affected area twice daily, in the morning and evening. Dosage of the topical solution may be increased in patients with resistant dermatoses.
However, dosing frequency should be decreased to once daily following clinical improvement.
For relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp, betamethasone valerate 0.12% foam should be applied twice daily, in the morning and evening. For application to the scalp, the can containing betamethasone valerate foam should be inverted and small amounts of the preparation placed on a saucer or other cool surface.
The foam should not be dispensed directly to the hands since the foam will begin to melt immediately upon contact with warm skin. Small amounts of the preparation should be massaged gently into the scalp until the foam disappears and entire scalp area has been treated.
For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, or tinea corporis caused by Trichophyton mentagrophytes, T. rubrum, or Epidermophyton floccosum, the fixed-combination cream or lotion containing betamethasone 0.05% and clotrimazole 1% should be applied sparingly and rubbed gently into the affected area twice daily, in the morning and evening.
If clinical improvement does not occur after 1 week in the treatment of tinea cruris or tinea corporis or after 2 weeks in the treatment of tinea pedis, the diagnosis should be reevaluated. The manufacturer states that dosage of the combination cream or lotion should not exceed 45 g or 45 mL per week, respectively, and duration of therapy with these combination preparations should not exceed 2 weeks in the treatment of tinea cruris or tinea corporis or 4 weeks in the treatment of tinea pedis. Occlusive dressings should not be used with these combination preparations.
For the topical treatment of plaque psoriasis (psoriasis vulgaris) in adults 18 years of age or older, the fixed-combination ointment containing betamethasone 0.05% and calcipotriene 0.005% should be applied and rubbed gently into the affected area until absorbed once daily.
The combination ointment should not be applied to greater than 30% of body surface area. The manufacturer states that dosage of the combination ointment should not exceed 100 g per week, and duration of therapy should not exceed 4 consecutive weeks. Occlusive dressings should not be used with the combination preparation, unless directed by a clinician.
The fixed-combination ointment should not be applied to the face, axillae, or groin area. The fixed-combination ointment should not be used in patients with erythrodermic, exfoliative, or pustular psoriasis or in patients with preexisting atrophy at the treatment site. Contact with the eyes should be avoided.
If irritation occurs, therapy with the fixed-combination ointment should be discontinued and appropriate treatment instituted. Patients should wash their hands after applying the drug. The fixed-combination ointment is not for ophthalmic, oral, or intravaginal use.
For the topical treatment of moderate to severe plaque psoriasis (psoriasis vulgaris) of the scalp in adults 18 years of age or older, the fixed-combination suspension containing betamethasone 0.05% and calcipotriene 0.005% should be applied to the affected area(s) on the scalp once daily for 2 weeks or until cleared.
The manufacturer states that dosage of the combination suspension should not exceed 100 g per week, and duration of therapy should not exceed 8 weeks. Occlusive dressings should not be used with the combination preparation, unless directed by a clinician. The combination suspension should not be applied to the face, axillae, or groin area.
In addition, the suspension should not be used in patients with erythrodermic, exfoliative, or pustular psoriasis or in patients with preexisting atrophy at the treatment site. Contact with the eyes should be avoided; eye irritation may occur. The bottle containing the suspension should be shaken prior to each use; patients should wash their hands after applying the drug.
The fixed-combination suspension is not for ophthalmic, oral, or intravaginal use.
Because calcipotriene may increase the effect of ultraviolet radiation to induce skin tumors, patients who apply the fixed-combination ointment or suspension to exposed areas of the body should avoid exposure to natural or artificial (e.g., sunlamps, tanning booths) sunlight and limit or avoid phototherapy.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| BETAMETHASONE VA 0.1% CREAM | Maintenance | Adults apply a thin layer to the affected area(s) by topical route once daily |
| BETAMETHASONE VALER 0.12% FOAM | Maintenance | Adults apply to the affected area(s) by topical route 2 times per day once in the morning and once at night |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| BETAMETHASONE VA 0.1% CREAM | Maintenance | Adults apply a thin layer to the affected area(s) by topical route once daily |
| BETAMETHASONE VALER 0.12% FOAM | Maintenance | Adults apply to the affected area(s) by topical route 2 times per day once in the morning and once at night |
The following drug interaction information is available for BETAMETHASONE VALERATE (betamethasone valerate):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for BETAMETHASONE VALERATE (betamethasone valerate):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hypothalamic-pituitary insufficiency |
The following adverse reaction information is available for BETAMETHASONE VALERATE (betamethasone valerate):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 15 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Folliculitis Purpura Skin and skin structure infection Skin atrophy |
| Rare/Very Rare |
|---|
|
Adrenocortical insufficiency Bullous dermatitis Cataracts Central serous chorioretinopathy Glaucoma Hypothalamic-pituitary insufficiency Ocular hypertension Skin hypopigmentation Skin striae Skin ulcer Urticaria |
There are 24 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Erythema Stinging of skin |
Acute pain at drug application site Blurred vision Headache disorder Paresthesia Pruritus of skin Skin rash Telangiectasia Treatment site sequelae |
| Rare/Very Rare |
|---|
|
Acneiform eruption Alopecia Blistering skin Contact dermatitis Dry skin Dyschromia Glycosuria Hirsutism Hypercortisolism Hyperesthesia Hyperglycemia Miliaria Perioral dermatitis Skin irritation |
The following precautions are available for BETAMETHASONE VALERATE (betamethasone valerate):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for BETAMETHASONE VALERATE (betamethasone valerate):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for BETAMETHASONE VALERATE (betamethasone valerate)'s list of indications:
| Allergic dermatitis | |
| L20 | Atopic dermatitis |
| L20.0 | Besnier's prurigo |
| L20.8 | Other atopic dermatitis |
| L20.81 | Atopic neurodermatitis |
| L20.82 | Flexural eczema |
| L20.83 | Infantile (acute) (chronic) eczema |
| L20.84 | Intrinsic (allergic) eczema |
| L20.89 | Other atopic dermatitis |
| L20.9 | Atopic dermatitis, unspecified |
| L23 | Allergic contact dermatitis |
| L23.0 | Allergic contact dermatitis due to metals |
| L23.1 | Allergic contact dermatitis due to adhesives |
| L23.2 | Allergic contact dermatitis due to cosmetics |
| L23.3 | Allergic contact dermatitis due to drugs in contact with skin |
| L23.4 | Allergic contact dermatitis due to dyes |
| L23.5 | Allergic contact dermatitis due to other chemical products |
| L23.6 | Allergic contact dermatitis due to food in contact with the skin |
| L23.7 | Allergic contact dermatitis due to plants, except food |
| L23.8 | Allergic contact dermatitis due to other agents |
| L23.81 | Allergic contact dermatitis due to animal (cat) (dog) dander |
| L23.89 | Allergic contact dermatitis due to other agents |
| L23.9 | Allergic contact dermatitis, unspecified cause |
| Atopic dermatitis | |
| L20 | Atopic dermatitis |
| L20.0 | Besnier's prurigo |
| L20.8 | Other atopic dermatitis |
| L20.81 | Atopic neurodermatitis |
| L20.82 | Flexural eczema |
| L20.84 | Intrinsic (allergic) eczema |
| L20.89 | Other atopic dermatitis |
| L20.9 | Atopic dermatitis, unspecified |
| Contact dermatitis | |
| L23 | Allergic contact dermatitis |
| L23.0 | Allergic contact dermatitis due to metals |
| L23.1 | Allergic contact dermatitis due to adhesives |
| L23.2 | Allergic contact dermatitis due to cosmetics |
| L23.3 | Allergic contact dermatitis due to drugs in contact with skin |
| L23.4 | Allergic contact dermatitis due to dyes |
| L23.5 | Allergic contact dermatitis due to other chemical products |
| L23.6 | Allergic contact dermatitis due to food in contact with the skin |
| L23.7 | Allergic contact dermatitis due to plants, except food |
| L23.8 | Allergic contact dermatitis due to other agents |
| L23.81 | Allergic contact dermatitis due to animal (cat) (dog) dander |
| L23.89 | Allergic contact dermatitis due to other agents |
| L23.9 | Allergic contact dermatitis, unspecified cause |
| L24 | Irritant contact dermatitis |
| L24.0 | Irritant contact dermatitis due to detergents |
| L24.1 | Irritant contact dermatitis due to oils and greases |
| L24.2 | Irritant contact dermatitis due to solvents |
| L24.3 | Irritant contact dermatitis due to cosmetics |
| L24.4 | Irritant contact dermatitis due to drugs in contact with skin |
| L24.5 | Irritant contact dermatitis due to other chemical products |
| L24.6 | Irritant contact dermatitis due to food in contact with skin |
| L24.7 | Irritant contact dermatitis due to plants, except food |
| L24.8 | Irritant contact dermatitis due to other agents |
| L24.81 | Irritant contact dermatitis due to metals |
| L24.89 | Irritant contact dermatitis due to other agents |
| L24.9 | Irritant contact dermatitis, unspecified cause |
| L24.A0 | Irritant contact dermatitis due to friction or contact with body fluids, unspecified |
| L24.A1 | Irritant contact dermatitis due to saliva |
| L24.A2 | Irritant contact dermatitis due to fecal, urinary or dual incontinence |
| L24.A9 | Irritant contact dermatitis due friction or contact with other specified body fluids |
| L24.B | Irritant contact dermatitis related to stoma or fistula |
| L24.B0 | Irritant contact dermatitis related to unspecified stoma or fistula |
| L24.B1 | Irritant contact dermatitis related to digestive stoma or fistula |
| L24.B2 | Irritant contact dermatitis related to respiratory stoma or fistula |
| L24.B3 | Irritant contact dermatitis related to fecal or urinary stoma or fistula |
| L25 | Unspecified contact dermatitis |
| L25.0 | Unspecified contact dermatitis due to cosmetics |
| L25.1 | Unspecified contact dermatitis due to drugs in contact with skin |
| L25.2 | Unspecified contact dermatitis due to dyes |
| L25.3 | Unspecified contact dermatitis due to other chemical products |
| L25.4 | Unspecified contact dermatitis due to food in contact with skin |
| L25.5 | Unspecified contact dermatitis due to plants, except food |
| L25.8 | Unspecified contact dermatitis due to other agents |
| L25.9 | Unspecified contact dermatitis, unspecified cause |
| Cutaneous t-cell lymphoma | |
| C84.0 | Mycosis fungoides |
| C84.A | Cutaneous t-cell lymphoma, unspecified |
| C84.A0 | Cutaneous t-cell lymphoma, unspecified, unspecified site |
| C84.A1 | Cutaneous t-cell lymphoma, unspecified lymph nodes of head, face, and neck |
| C84.A2 | Cutaneous t-cell lymphoma, unspecified, intrathoracic lymph nodes |
| C84.A3 | Cutaneous t-cell lymphoma, unspecified, intra-abdominal lymph nodes |
| C84.A4 | Cutaneous t-cell lymphoma, unspecified, lymph nodes of axilla and upper limb |
| C84.A5 | Cutaneous t-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
| C84.A6 | Cutaneous t-cell lymphoma, unspecified, intrapelvic lymph nodes |
| C84.A7 | Cutaneous t-cell lymphoma, unspecified, spleen |
| C84.A8 | Cutaneous t-cell lymphoma, unspecified, lymph nodes of multiple sites |
| C84.A9 | Cutaneous t-cell lymphoma, unspecified, extranodal and solid organ sites |
| Dermatosis of the scalp | |
| L21.0 | Seborrhea capitis |
| L23.0 | Allergic contact dermatitis due to metals |
| L23.1 | Allergic contact dermatitis due to adhesives |
| L23.2 | Allergic contact dermatitis due to cosmetics |
| L23.3 | Allergic contact dermatitis due to drugs in contact with skin |
| L23.4 | Allergic contact dermatitis due to dyes |
| L23.5 | Allergic contact dermatitis due to other chemical products |
| L23.8 | Allergic contact dermatitis due to other agents |
| L23.9 | Allergic contact dermatitis, unspecified cause |
| Discoid lupus erythematosus | |
| H01.12 | Discoid lupus erythematosus of eyelid |
| H01.121 | Discoid lupus erythematosus of right upper eyelid |
| H01.122 | Discoid lupus erythematosus of right lower eyelid |
| H01.123 | Discoid lupus erythematosus of right eye, unspecified eyelid |
| H01.124 | Discoid lupus erythematosus of left upper eyelid |
| H01.125 | Discoid lupus erythematosus of left lower eyelid |
| H01.126 | Discoid lupus erythematosus of left eye, unspecified eyelid |
| H01.129 | Discoid lupus erythematosus of unspecified eye, unspecified eyelid |
| L93.0 | Discoid lupus erythematosus |
| Genital organ pruritus | |
| L29.2 | Pruritus vulvae |
| L29.3 | Anogenital pruritus, unspecified |
| Granuloma annulare | |
| L92.0 | Granuloma annulare |
| Lichen simplex chronicus | |
| L28.0 | Lichen simplex chronicus |
| Plaque psoriasis | |
| L40.0 | Psoriasis vulgaris |
| L40.9 | Psoriasis, unspecified |
| Pruritus ani | |
| L29.0 | Pruritus ani |
| L29.3 | Anogenital pruritus, unspecified |
| Pruritus of skin | |
| L29.8 | Other pruritus |
| L29.81 | Cholestatic pruritus |
| L29.89 | Other pruritus |
| L29.9 | Pruritus, unspecified |
| Pyoderma gangrenosum | |
| L88 | Pyoderma gangrenosum |
| Scalp psoriasis | |
| L40.0 | Psoriasis vulgaris |
| L40.1 | Generalized pustular psoriasis |
| L40.4 | Guttate psoriasis |
| L40.8 | Other psoriasis |
| L40.9 | Psoriasis, unspecified |
| Seborrheic dermatitis | |
| L21 | Seborrheic dermatitis |
| L21.0 | Seborrhea capitis |
| L21.1 | Seborrheic infantile dermatitis |
| L21.8 | Other seborrheic dermatitis |
| L21.9 | Seborrheic dermatitis, unspecified |
| Skin inflammation | |
| L20 | Atopic dermatitis |
| L20.8 | Other atopic dermatitis |
| L20.89 | Other atopic dermatitis |
| L20.9 | Atopic dermatitis, unspecified |
| L21 | Seborrheic dermatitis |
| L21.8 | Other seborrheic dermatitis |
| L21.9 | Seborrheic dermatitis, unspecified |
| L25 | Unspecified contact dermatitis |
| L30.8 | Other specified dermatitis |
| L30.9 | Dermatitis, unspecified |
| L40 | Psoriasis |
| L40.1 | Generalized pustular psoriasis |
| L40.8 | Other psoriasis |
| L40.9 | Psoriasis, unspecified |
| R21 | Rash and other nonspecific skin eruption |
Formulary Reference Tool